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Abstract: Heparin-binding EGF-like growth factor (HB-EGF) belongs to the EGF family 
of growth factors. It is biologically active either as a molecule anchored to the membrane 
or as a soluble form released by proteolytic cleavage of the extracellular domain. HB-EGF 
is involved in relevant physiological and pathological processes spanning from 
proliferation and apoptosis to morphogenesis. We outline here the main activities of  
HB-EGF in connection with normal or neoplastic differentiative or proliferative events 
taking place primitively in the hematopoietic microenvironment. 
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1. HB-EGF 
Heparin-binding epidermal growth factor-like growth factor (HB-EGF, Figure 1) was first 
described by Higashiyama and Coll [1,2], in 1991/92, as a heavily glycosylated EGF family member 
of approximately 22 kD that was released by macrophage-like U-937 cell line, showing heparin 
affinity and eliciting mitogenic activities in BALB-3T3 fibroblasts and smooth muscle cells, but not in 
endothelial cells. As a member of the EGF family, it bound to EGF receptors on A-431 epidermoid 
carcinoma cells and smooth muscle cells, and was a more potent mitogen for smooth muscle cells than 
EGF. HB-EGF was also described as expressed in cultured human macrophages and involved in 
macrophage-mediated cellular proliferation. It turned out that membrane-anchored HB-EGF and the 
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sole receptor for diphtheria toxin were one and the same molecule [3–5]. Diphtheria toxin binds to  
HB-EGF [5] and after internalization inhibits protein synthesis, an event that usually triggers apoptotic 
death [6]. It is now recognized that HB-EGF is expressed in a wide range of cell types, including 
monocytes/macrophages [1], CD4+ lymphocytes [7,8], neutrophils [9], eosinophils [10], myeloid 
leukemia blasts [11], myeloma cells [12], vascular smooth muscle cells [13], endothelial [14] and 
normal [15], or neoplastic [16–18] epithelial cells. HB-EGF binds to EGFR/ErbB1/HER1 and 
ErbB4/HER4 [1,2,19] (Table 1) eliciting different biological responses [17,19]. Membrane-anchored 
HB-EGF functions as a cell-to-cell adhesion protein [20] that exerts mainly inhibitory juxtacrine 
activities involved in cell cycle arrest and growth inhibition [21] as well as resistance to  
apoptosis [22,23]. HB-EGF may also be cleaved and released from cell upon stimulation with a variety 
of molecules capable of activating integral membrane metalloproteases with a disintegrin domain 
(ADAMs) 9, 10, 12, and 17 that can be viewed as activators of the paracrine form of HB-EGF [24–29]. 
Soluble HB-EGF acts variously on sensitive bystander cells, including mitogenic and chemotactic 
effects on monocytes/macrophages [1], fibroblasts [7], and SMC [30,31], chemotaxis on endothelial 
cells [30], astrocytes [32], and growth activity for normal and neoplastic epithelial cells [8,15]. The 
shedding process generates a kind of autocrine mitogenic signal on the releasing cells themselves via 
nuclear translocation of either full-length proHB-EGF [33] or its truncated cytoplasmic tail [34] 
(Figure 1). HB-EGF is involved in orchestrating inflammation [18], atheromatous plaque  
progression [8], and wound healing [7,8,35,36]. It participates in stromal proliferation following 
decidualization [37], and in autocrine-paracrine loops, which are active in a number of epithelial 
neoplasias [8,18], by promoting tumor growth as a direct mitogen for neoplastic cells [8,18,38,39] or a 
microenvironment modifier by inducing angiogenesis [7,8,18,31,39–41] and recruiting a variety of 
cells [7,8,18,42–44]. Either membrane-anchored or soluble HB-EGF has a role in directing the 
proliferation and differentiation of stromal stem cells [45] and in epithelial-to-mesenchymal  
transition [46]. Due to its heparin-binding domain, a unique property of the EGF receptor family 
ligands, HB-EGF is able to bind to heparan-sulphate proteoglycans, which may further modulate its 
biological activity [17]. Such heterogeneous and proteiform activities make sense based on the 
evolutionary and functional history of this growth factor. A molecule involved in proliferation [1], 
apoptosis [21,23], cell migration [42,43], differentiation [45], morphogenesis, and  
development [47–51], HB-EGF emerged as a microenvironment organizer, a factor contributing to, 
and acting in, niches where normal stem and progenitor cells are maintained and ordinately released 
into differentiation and where oncogenic processes take place and keep developing. 
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Figure 1. Basic structure, functional domains, and processing of HB-EGF. 
 
Table 1. EGF family receptors and ligands.  
EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4 
HB-EGF  NRG1/2 HB-EGF 
EGF   NRG1/2/3/4 
TGF-α   BTC 
AR   EPR 
BTC    
EPR    
ErbB/HER homo- and heterodimers activated by HB-EGF 
1/1 - 1/2 - 1/3 - 1/4 - 2/4 - 3/4 - 4/4 
TGF-α, transforming growth factor-α; AR, amphiregulin; BTC, betacellulin;  
EPR, epiregulin; NRG1/4, neuregulin-1/4. 
2. EGF Family Members, Cognate Receptors, and Layers of Regulation 
The members of the EGF family include four groups of growth factors binding to specific cognate 
receptors (EGFR/ErbB1/HER1, ErbB2/HER2 to ErbB4/HER4). Upon ligand binding, the receptors 
associate to form a variety of di/oligomeric complexes acting as intrinsic tyrosine kinases [35–37]. As 
shown in Table 1, EGF ligands bind to specific receptors with a degree of crossreactivity also due to 
the assortment of these complexes. Soluble and membrane-anchored HB-EGF bind to, and activate, 
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EGFR [1,4], ErbB4 [19,55], and complexes of these receptors [53,54,56]. HB-EGF also binds to 
heparan sulfate proteoglycans [55,57], and N-arginine of dibasic convertase [42]. ErbB receptors are 
expressed within numerous tissues and systems where they may mediate different activities depending 
on the ligand, its sterical organization (membrane-anchored or soluble receptor), and its receptor 
affinity. For example, soluble HB-EGF ligation of EGFR mediates strong proliferative effects [38,39], 
while the ligation of ErbB4 mediates chemotactic responses [19]. Instead, through the same receptors 
membrane-bound HB-EGF may mediate growth inhibition and functional responses [21–23]. 
Therefore there is a level of regulation, based on the molecule topology, which leads to biochemical 
differences and different resulting activities [58]. A major difference is that membrane-anchored  
HB-EGF is believed to induce extended polymerization of ErbB receptors, whereas soluble HB-EGF 
probably induces smaller receptor complexes, usually in form of homo/heterodimers or small 
oligomers. Extended complexes imply a variety of heterogeneous cell-to-cell interactions including 
coreceptors activities, and sending, usually, inhibitory signals. Smaller complexes imply selective 
receptor stimulation and send activatory signals [58]. Finally, heparan sulfate proteoglycans on the cell 
membrane may regulate the activity of HB-EGF [57] and the expression of N-arginine of dibasic 
convertase enhances the migration induced by HB-EGF via EGFR [42]. In other words, a further 
source of cellular signaling is the transmembrane/cytoplasmic fragment of HB-EGF, either as part of 
full-length internalized proHB-EGF [33,59] or as truncated transmembrane/cytoplasmic fragment 
remaining after the ADAM-dependent release of the ectodomain portion [34,59]. Under stimulus this 
transmembrane/cytoplasmic fragment translocates to the nucleus and binds to transcriptional cyclin A 
repressor promyelocytic leukemia zinc finger protein [34] or to transcriptional cyclin D2 repressor 
Bcl6 [60] promoting S-phase entry. Also, the phosphorylation of the cytoplasmic domain of HB-EGF 
due to external stimuli plays a role in HB-EGF-related tumorigenesis [61]. Therefore the cells and 
enzymes available in the microenvironment add a further layer of local regulation to HB-EGF 
biological activities. Enhanced expression, constitutively active mutant forms, autocrine activation of 
the ErbB receptors, and increased HB-EGF production are observed in human cancers and may be 
associated with poor outcomes. Therapeutic strategies targeting EGFR, ErbB2 [62] or  
HB-EGF [63–65] have been suggested or even used in medical practice. 
3. HB-EGF-Dependent EGFR Phosphorylation and Transduction Pathways 
HB-EGF induces receptor association, intrinsic tyrosine kinase-dependent autophosphorylation of 
specific tyrosine residues that serve as docking sites for intracellular signaling molecules, and activates 
a signaling cascade to nucleus followed by cell proliferation [1], differentiation [45] or  
chemotaxis [42] depending on the receptors that are involved. Upon HB-EGF, for example, EGFR 
activates intrinsic protein tyrosine kinase activities that phosphorylate specific tyrosine residues within 
the cytoplasmic domain [66]. By performing mass spectrometry analysis of trypsin digested peptides 
on HeLa cells we observed that HB-EGF induces EGFR phosphorylation at tyrosines 992, 1045, 1068, 
1086, 1148, 1173, and at serine 1142. In contrast, there is no phosphorylation of tyrosine 1045, little 
phosphorylation of serine 1142, and as a rule, HB-EGF-induced HER1 phosphorylation shows a 
pattern somewhat different from that induced by other EGFR ligands [18,67]. Tyrosines 1068 and 
1173 are two major sites of autophosphorylation that autophosphorylated, to very different degrees, 
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following HB-EGF [18]. Autophosphorylation of EGFR tyrosines 1068 and 1173 is followed by the 
activation of Ras, MEK, and ERK1/2 pathways [68]. For example, following stimulation of HeLa cells 
with HB-EGF, ERK1/2 phosphorilates at threonine 185 and tyrosine 187 [18,67]. 
4. GPCR-Dependent Transactivation of EGFR 
Ligation of G-protein (heterotrimeric guanine nucleotide-binding protein)-coupled receptors 
(GPCRs) leads to ADAM-dependent cleavage [69] of membrane-anchored HB-EGF into a soluble 
form of HB-EGF [24,70] capable of activating ErbB receptors on the same cell or on bystander  
cells [71,72]. Indeed, the transactivation of EGFR is a general function of GPCR  
signaling [18,24,67,73–77], which has been described in diverse cell types including fibroblasts, 
keratinocytes, astrocytes and smooth muscle cells [18,58,73]. Deregulated GPCR-dependent release of 
HB-EGF has been associated with hyperplastic tissue abnormalities [78]. Critical mitogenic effects 
through extracellular transactivation of EGFR follow to stimulation with GPCRs ligands including 
endothelin-1, lysophosphatidic acid [50], angiotensin-II [73] or CXC chemokine ligand 12 (CXCL12, 
stromal cell-derived factor-1) [18] via ADAMs 10, 12, or 17 depending on the ligand, GPCR, and cell 
type [24–29,79]. We demonstrated that CXCL12 transactivates EGFR through ectodomain shedding of 
HB-EGF [18,67]. CXCL12 binds to GPCRs CXC receptor 4 and 7 (CXCR4 and CXCR7) [80], and 
activates ADAM 10 at least in macrophages [18,67,81–83] and might increase the release of  
ADAM 17 [84]. Interestingly, ADAM 10 mediates also the cleavage of Notch and its ligand  
Delta [85]. The CXCL12-dependent HB-EGF transactivation mechanism is relevant to hematopoietic 
differentiation as well as leukemia progression [86]. Besides its role in development [87], CXCL12 
regulates important hematopoietic functions, induces cell adhesion and chemotaxis, and coordinates 
the circulation of hematopoietic stem cells, lymphocytes and monocytes/macrophages [86,88–91]. 
Stromal and endothelial cells constitutively express CXCL12 in bone marrow, lymph nodes, liver, lung 
and skin [92]. CXCL12 may induce mitotic signals, favor tissue invasion, and contribute to the 
development of a microenvironment infiltrated by M2-polarized macrophages that support cell 
survival [91,93]. Cancer cells usually express functional receptors for CXCL12 [67,89,90,94] and 
some cancers constitutively express CXCL12 [18,95].  
5. GPCR-Dependent Transinhibition of EGFR 
By binding to its receptors, CXCL12 may transactivate EGFR. As described above, for example, 
the ligation of CXCR4 activates membrane ADAMs that release HB-EGF from cell membrane, 
resulting in its binding to EGFR [24,69–72]. This induces a signaling cascade that is involved in 
pivotal phenomena such as proliferation or differentiation as well as morphogenesis depending on the 
microenvironmental context [18,50,73]. Usually, the transactivation occurs in a paracrine manner. In 
EGFR/GPCR double-positive cells, however, a transactivation along intracytoplasmic pathways has 
been reported [96] and shown to be important in breast cancer [97] and myeloma progression [98]. 
Furthermore, we provided evidence that in EGFR/CXCR4 double-positive cells CXCL12 may 
transinhibit EGFR [67]. Downstream of CXCR4, CXCL12 elicits signals via both G protein-dependent 
and β-arrestin-dependent pathways responsible for inducing rapid and late waves, respectively, of 
ERK1/2 phosphorylation [99–101]. In HeLa and 5637 cancer cell lines, CXCL12 elicits an 
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intracytoplasmic G-protein-dependent calmodulin/calcineurin pathway leading to a delayed 
autophosphorylation peak of EGFR that is reverted by later β-arrestin activation. The synthetic [N33A] 
CXCL12 [102] that activates preferentially G protein-dependent pathways and fails to activate  
β-arrestin-dependent ERK1/2 phosphorylation downstream of CXCR4 [67] can completely block 
EGFR phosphorylation [67]. Therefore a EGFR/CXCR4 double-positive cell may shed HB-EGF to 
tyransactivate bystander EGFR-positive cells [24,69–72], transiently delay the activation of its own 
EGFR [67] and enter into S-phase due to nuclear translocation of the cytoplasmic tail of HB-EGF [34]. 
This process can be expected to strengthen a gradient of cell proliferation along differentiation 
pathways functional to the maintenance of hematopoietic niches.  
6. Factors Inducing HB-EGF in Hematopoietic Cells 
A great variety of human hematological cell lines except for the B-derived ones, and blasts from a 
majority of acute myeloid leukemia cases express and release a fully functional HB-EGF molecule. 
These cells express HB-EGF mRNA, are sensitive to the cytolytic effect of diphtheria toxin exposure, 
and release soluble HB-EGF that exerts a strong proliferative effect on BALB/c-3T3 cells [11]. The 
expression of HB-EGF mRNA in these cells is strongly modified by factors relevant to the biology of 
hematopoietic cells at different stages of differentiation. DMSO, PMA, ATRA, IFNγ, 1α,25-(OH)2D3, 
and TNFα, are known to induce biological effects such as proliferation or differentiation in normal or 
neoplastic cells of different hematopoietic lineage. PMA, DMSO and, more interestingly, TNFα, 
1α,25-(OH)2D3, and especially ATRA, and costimulation with TNFα and ATRA induce an increase in 
transcripts for HB-EGF in either cell lines or ex vivo cells [9,11]. GM-CSF and CXCL12 also induce 
HB-EGF in a number of human cell lines, in human monocytes/macrophages, neutrophils, and ex vivo 
cancer cells, including acute leukemia cells [9,11,18]. For example, GM-CSF induces HB-EGF mRNA 
and acquisition of sensitivity to diphtheria toxin in neutrophils and acute myeloid leukemia cells that 
were previously HB-EGF-negative [9,11]. In HB-EGF promoter, putative binding sites for NF-kB, 
AP1, SP1, SP3 have been identified [103]. In addition, it has been shown that HB-EGF can be induced 
through Ras pathway activation [104,105]. TNFα has been reported to mobilize NF-kB [106]; the 
receptors for vitamins A and D, including 1α,25-(OH)2D3, recognize common response elements 
containing the AP1 site [107]; by binding to the β-subunit of its receptor, GM-CSF activates Ras and 
Raf-1 and the MAP kinase pathway [108]. Therefore, TNFα , ATRA, 1α,25-(OH)2D3, GM-CSF, and 
CXCL12 have the HB-EGF gene as a downstream target [9,11]. HB-EGF is intensely expressed along 
the hematopoietic cell differentiation by myeloid [11] and lymphoid progenitors too. Outside the 
hematopoietic system, there is convincing evidence that HB-EGF is involved in developmental tasks. 
Pancreatic and duodenal homeobox-1 is also a direct regulator of HB-EGF [109]. The Wilms’ tumor 
gene contributes to the regulation of the EGF family ligands during nephrogenesis [110]. Direct 
interaction between MyoD and the HB-EGF promoter is transiently found during skeletal muscle cell 
differentiation and the membrane form of HB-EGF is expressed preferentially in myotubes [48]. 
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7. HB-EGF in Hematopoietic Microenvironment 
HB-EGF plays a role in regulating the differentiation of stromal stem cells [45] and the proliferation 
of hematopoietic maturing cells, themselves a source of HB-EGF [9,11]. However, to describe the role 
of HB-EGF, it is important to stand back and take a broad view of how hematopoietic developmental 
tasks fit into the organization of what we commonly call the hematopoietic bone marrow 
microenvironment. Hematopoietic differentiation is characterized by a number of quite well 
recognized stages. At each differentiative stage, immature cells are present with progressively 
restricted potential towards the differentiation into blood cells. The differentiation cascade is formed 
by hematopoietic stem cells and hematopoietic progenitors from which all lineages of blood originate. 
Hematopoietic stem and progenitor cells seem to be nurtured in sites or niches where cell-to-cell 
interaction regulate the output of appropriate numbers of blood cells by ensuring hematopoietic stem 
cell survival and self-renewal [111,112]. The specific hematopoietic stem cell niche allows stem cells 
to proliferate, prevents them from differentiating, preserving their differentiation potential, and keeps 
them in place [45,112]. After leaving the stem cell niche, cells can differentiate. Though a variety of 
cell types have been involved in promoting this regulatory microenvironment [113],  
CXCL12-expressing reticular cells seem to play a fundamental role [114]. The microenvironment is 
dynamic and the number of niche cells can correlate with the number of hematopoietic stem  
cells [115]. The turnover and persistence of the niche is assured by CXCR4, the primary receptor for 
CXCL12 [80], which plays a pivotal role in maintaining hematopoietic stem cells, early B cell 
precursors and plasma cells in strict contact with the above-mentioned CXCL12-abundant reticular 
cells [92,93,114,116,117]. Though hematopoietic stem cells are slowly cycling and some are  
dormant [118–120], lineage-restricted progenitors are cycling actively [121]. CXCL12-abundant 
reticular cells maintain blood progenitor cells in a proliferative state. Signals that regulate differentially 
the proliferation of hematopoietic precursors may be elicited by TGF-β [122], angiopoietin-1 [123], 
Wnt [124], and HB-EGF [9,11,45,125]. Other proteins such as those belonging to Notch family may 
play a role, which seems to be less relevant than that played by the CXCL2/CXCR4 axis [126]. 
CXCL12-abundant reticular cells produce hematopoietic cytokines, CXCL12 and SCF [127]. As 
adipo-osteogenic progenitors, they may differentiate into mature cells that produce protein for bone 
formation or store energy [45]. Interestingly, cortical thymic epithelial cell compartment is required for 
early stages of T cell development in the thymus [128]. Cortical thymic epithelial cells express 
CXCL12 and the Notch ligand Delta-like 4 [129], thus providing signals for the attraction, survival and 
differentiation for T lymphocyte progenitors [130]. CXCL12-abundant reticular cells release CXCL12 
that is able to cleave HB-EGF from bystander cells [24,70–72] that in turn inhibits CXCL12-abundant 
reticular cell maturation [45,67]. Due to their CXCR4 expression [86], either normal hematopoietic or 
leukemic cells share a preferential homing into the bone marrow, namely into niches with  
CXCL12-rich ancillary stromal cells [45,92]. There, CXCL12 transactivates EGFR [18] that is mainly 
expressed by stromal cells and stem cells [45]. Finally, the release of the ectodomain fragment of  
HB-EGF transactivates EGFR in bystander cells but leads to intracellular transinhibition of EGFR [67] 
as well as nuclear translocation of the transmembrane/cytoplasmic proHB-EGF fragment, which 
promotes cell cycling [34,58–60]. Therefore hematopoietic progenitor cells increase their proliferative 
potential entering the differentiation process by the combined effect of CXCL12-dependent shedding 
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of HB-EGF and the intracellular release of HB-EGF transmembrane/cytoplasmic tail to translocate to 
nucleus to generate mitogenic signals [34]. The regulation of the tyrosine kinase activity of EGFR 
associated with the activation of cell cycling via direct nuclear factor mobilization further contributes a 
gradient of cell proliferation and differentiation functional to a flexible and dynamic maintenance of 
hematopoietic niches. Through chemotaxis and EGFR transactivation, CXCL12 promotes the shaping 
of niches where stromal and hematopoietic stem cells strictly interact in order to maintain the 
hematopoietic function (Figure 2). 
Figure 2. HB-EGF network relevant to hematopoietic niche. Cell-to-cell interactions and 
gradients of cell-shed factors, including CXCL12 and HB-EGF, lock both hematopoietic 
and stromal stem cells in the hematopoietic niche where they support each other to keep 
surviving as undifferentiated cells. Hematopoietic differentiation implies both asymmetric 
hematopoietic stem cell mitosis and maturing progenitor escape from the niche 
microenvironment partly due to receptor modulation.  
 
8. CXCL12- and HB-EGF-Related Loops in Hematopoiesis 
HB-EGF may be transcriptionally and/or functionally regulated by factors such as TNFα, ATRA, 
1α,25-(OH)2D3, GM-CSF, and CXCL12 [9,11,18] that are important for effective and coordinate 
hematopoiesis. Endothelial and stromal cells in bone marrow constitutively express CXCL12 [92] that 
induces cytokines that share protean activities involving cell growth and  
differentiation [22,39,86,87–91,93]. The axis CXCL12/CXCR4 (and possibly CXCL12/CXCR7) may 
be thought of as a node connecting numerous loops to the highly complex loops involving the EGF 
family and its receptors, namely HB-EGF/EGFR [53]. In the context of the hematopoietic system, the 
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crosstalk between CXCL12/CXCR4 and HB-EGF/EGFR contributes to the balance between cellular 
responses of differentiation and self-renewal that depend on the stimulation of EGFR [18,131]. Soluble 
HB-EGF inhibits the multilineage differentiation of stromal stem cells maintaining them open to 
proliferation [45] and available for cell-to-cell contact with hematopoietic stem cells in the specialized 
niches. In contrast, proliferation of hematopoietic progenitors changes from maximal to minimal 
according to the decreasing gradient of CXCL12 away from the niches. In the niches the balance is 
tipped preferentially to a self renewal-type of regulation in which the stromal environment participates 
actively [18,45,67,132,133]. Near the niches hematopoietic progenitors proliferate actively and start 
their differentiative journey. The hematopoietic microenvironment, therefore, is at the crossroad of 
regulated self-renewal and oncogenesis and links typically oncogenes and inflammation [134]. 
Interestingly, terminally differentiated neutrophils, monocytes/macrophages and lymphocytes may also 
coexpress CXCR4 and HB-EGF [9,11,18]. These cells are sensitive to CXCL12, upon which they 
release HB-EGF, share aptness to infiltrate normal tissues and cancers and to act either inducing niches 
supporting cancer stem cells as well as suppressing or fostering immunity. These infiltrating cells seem 
to reproduce a cancer/stromal microenvironment supporting cancer stem cells somehow similar to the 
hematopoietic environment. It seems indeed that oncogenesis is primarily coupled to niches [113]. 
This has suggested a role for the therapeutic use of inhibitors of the CXCL12/CXCR4 [135] and  
HB-EGF/EGFR [62–65] axes in the clinical setting, namely targeted to eradicate cancer stem cells that 
survive in the niches [136]. 
9. HB-EGF in Leukemia 
Leukemia encompasses a heterogeneous group of hematological malignancies characterized by a 
growth of immature (acute leukemias) or variously maturing (chronic leukemias) cells within the bone 
marrow. Clinical manifestations of acute leukemia include leukocytosis and deficient normal 
hematopoietic function due to leukemic cells infiltrating the bone marrow [137,138]. Chronic 
leukemias, including myeloproliferative and lymphoproliferative disorders, show progressive 
leukocytosis due to accumulation of more or less mature circulating blood cells and deficient 
hematopoietic function as a late event. They may change their biology and undergo progression to 
more rapidly evolving conditions, including disorders strictly resembling acute leukemia [139,140]. 
Perhaps it is not surprising that leukemia might develop by taking over hematopoietic stem cell niches. 
The relevant role played by ancillary cells in normal hematopoiesis and some emerging models 
suggest a role for bone marrow microenvironment in disease maintenance and resistance as well as in 
leukemia initiation and progression [113]. Though the predominant views have been developed in the 
setting of epithelial cancers, there are data supporting that leukemic cell survival and proliferation may 
be fostered by niche specific signaling and/or that leukemic cells may modify the microenvironment in 
order to ease their progression and/or that disruption of signaling between hematopoietic stem cells 
and their niches promote cancer initiation [113]. A number of cells and factors that govern cell-to-cell 
interactions and the processes in the bone marrow niches have emerged. CXCL12 [67,114,127] and 
HB-EGF via its dual signaling [11,18,45,125,141] play a role in remodeling hematopoietic niches 
allowing for stem cell maintenance and regulated differentiation vs. proliferation of hematopoietic 
progenitors. Most leukemias overexpress HB-EGF [11,63], CXCR4 [136,142], and even  
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CXCL12 [143]. Leukemia-involved cytokines such as TNFα [144,145] and GM-CSF [9,11], or 
hematopoietic differentiation-related factors such as ATRA and 1α,25-(OH)2D3 [11], have the  
HB-EGF gene as a downstream target and strongly increase HB-EGF expression [9,11]. Chronic 
myeloid leukemia cells express the chimeric protein BCR/ABL related to the (9;22) translocation, 
which plays a relevant pathogenetic role in this leukemia [146]. HB-EGF is one of the molecules 
transcriptionally induced by the chimeric protein BCR/ABL through activation of the Ras and MAP 
kinase pathways. Therefore the same factors that play a central role in the hematopoietic niche are 
involved in leukemia biology [136]. The hematopoietic niche is remodeled by these factors including 
HB-EGF to represent a protective microenvironment orchestrating a great deal of stimuli favoring 
leukemia initiation, progression, post-treatment persistence as minimal residual disease, and relapse.  
10. HB-EGF in Multiple Myeloma 
Multiple myeloma is another malignancy that grows within the bone marrow as a clonal expansion 
of plasma cells. Over unpredictable time periods, the disease leads to osteolytic bone lesions, 
hypercalcemia, insufficient haematopoietic function, and anomalous angiogenesis [147,148]. Multiple 
myeloma is preceded by an asymptomatic premalignant phase associated with bone marrow alterations 
suggesting microenvironment defects that favor the survival of plasma cells. It seems that additional 
bone marrow changes are needed for overt myeloma to develop [149]. Myeloma cells take over 
hematopoietic stem cell niches in bone marrow. A number of molecules relevant to normal 
haematopoiesis play a part in the biology of myeloma cells such as IL-6, VEGF, osteopontin, 
angiopoietin-1, Notch, Wnt, Hedgehog, and DKK1 protein [12,149–152]. Moreover, both homing and 
survival of myeloma cells largely depends on the CXCL12/CXCR4 axis [152,153]. CXCR4 has been 
targeted in the clinical setting of multiple myeloma with promising results [154]. EGF-family members 
such as NRG1, AR, and HB-EGF, which are expressed by cells from hematopoietic niches, can bind to 
heparan-sulphate proteoglycans on myeloma cells to promote myeloma growth [12,98,149,150,155]. 
The crosstalk between CXCL12/CXCR4 and HB-EGF/EGFR contributes in this case a direct 
proliferative stimulus to myeloma cells. However, the primary activity of these loops assures the 
survival of myeloma stem cells or anything similar inside the bone marrow niches [4,20,156]. In such a 
protective environment, mainly depending on cell-to-cell interactions based on fundamental players 
like CXCL12, Notch, and HB-EGF [152], myeloma stem cells can persist as minimal disease surviving 
treatment to relapse eventually as overt myeloma. EGF-signaling has been proposed as a promising 
target for myeloma treatment [149,155].  
11. Final Remarks 
The role of HB-EGF in hematopoiesis is somehow surprising to us. HB-EGF is an ancient player on 
the field of evolution, where it plays a role in fundamental signaling mechanisms that are also involved 
in hematopoietic stem cell niches. It participates to such events in association with a variety of other 
factors and together they orchestrate the complex network of hematopoietic regulated differentiation. 
Due to the relevance of the bone marrow niches for oncogenesis, HB-EGF represents a molecule 
relevant to the biology of hematopoietic malignancies that develop primarily in the bone marrow 
microenvironment such as acute and chronic either myeloid or lymphoid leukemias, as well as multiple 
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myeloma. It is possible that we can expect that the role of the bone marrow microenvironment is not a 
great deal different for malignancies arising in periphery and infiltrating the hematopoietic bone 
marrow secondarily. The relevance of these mechanisms is also supported by the promising results of 
targeted treatments in the preclinical and clinical setting. However, the very mechanisms, crosstalks 
and cell types fundamental for regulated differentiation in the hematopoietic system as well as their 
fine-tuning and global significance are far from being elucidated. 
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